InspireMD’s CGuard™ MicroNet™ EPS Featured in a Live Case Transmission to the 2nd DGA Interventional Congress
June 11 2018 - 9:53AM
InspireMD, Inc. (NYSE AMER:NSPR), a leader in embolic prevention
systems (EPS) / thrombus management technologies and neurovascular
devices, today announced that its CGuard™ MicroNet™ covered Embolic
Prevention System (EPS) was successfully featured in a live case
transmission on June 8th to the 2nd DGA Interventional Congress of
the DGA-Akademie GmbH, the academy for vascular medicine in
Hamburg, Germany.
The focus of this angiology congress is
presentation and objective discussion of new diagnostic and
therapeutic strategies in arterial and venous disease among leading
endovascular physicians, interventional cardiologists,
interventional radiologists and interventional neuroradiologists
from across Europe
Dr. Ralf Langhoff, Medical Director of
Angiology/Vascular Medicine, St. Gertrauden-Krankenhaus in Berlin,
performed a challenging live endovascular procedure on a 77
year-old male patient with 80% restenosis of the right internal
carotid artery following surgical endarterectomy in 2017, which is
considered the current gold standard. The procedure featured
CGuard™ EPS and was transmitted real time to the congress.
Dr. Langhoff commented, “CGuard™ EPS is becoming
an important tool for the treatment of patients with carotid artery
disease. The patented MicroNet™ technology offers plaque
protection, while the product exhibits no foreshortening and
delivers excellent conformability. The live case we performed went
extremely well and clearly highlights the advantages of CGuard™ EPS
in the treatment of carotid artery disease. CGuard™ EPS is
making carotid artery stenting an increasingly viable alternative
to the surgical carotid endarterectomy procedure.”
“It is an honor to have our technology featured at
this leading industry conference by Dr. Ralf Langhoff, one of the
premier vascular interventionalists in Europe,” commented James
Barry, PhD, Chief Executive Officer of InspireMD. “The DGA
Interventional Congress is one of the most prominent conferences in
the field of vascular surgery and interventional medicine featuring
new developments in therapeutic strategies and technologies, and
brings together top key opinion leaders from around the world.”
About InspireMD, Inc.InspireMD seeks to utilize
its patented MicroNet™ technology to make its products the industry
standard for embolic protection and to provide a superior solution
to the key clinical issues of current stenting in patients with a
high risk of distal embolization, no reflow and major adverse
cardiac events.
InspireMD intends to pursue applications of this
MicroNet technology in coronary, carotid (CGuard™), neurovascular,
and peripheral artery procedures. InspireMD's common stock is
quoted on the NYSE American under the ticker symbol NSPR and
certain warrants are quoted on the NYSE American under the ticker
symbol NSPR.WS.
Forward-looking StatementsThis press release
contains "forward-looking statements." Such statements may be
preceded by the words "intends," "may," "will," "plans," "expects,"
"anticipates," "projects," "predicts," "estimates," "aims,"
"believes," "hopes," "potential" or similar words. Forward-looking
statements are not guarantees of future performance, are based on
certain assumptions and are subject to various known and unknown
risks and uncertainties, many of which are beyond the Company's
control, and cannot be predicted or quantified and consequently,
actual results may differ materially from those expressed or
implied by such forward-looking statements. Such risks and
uncertainties include, without limitation, risks and uncertainties
associated with (i) market acceptance of our existing and new
products, (ii) negative clinical trial results or lengthy product
delays in key markets, (iii) an inability to secure regulatory
approvals for the sale of our products, (iv) intense competition in
the medical device industry from much larger, multinational
companies, (v) product liability claims, (vi) product malfunctions,
(vii) our limited manufacturing capabilities and reliance on
subcontractors for assistance, (viii) insufficient or inadequate
reimbursement by governmental and other third party payers for our
products, (ix) our efforts to successfully obtain and maintain
intellectual property protection covering our products, which may
not be successful, (x) legislative or regulatory reform of the
healthcare system in both the U.S. and foreign jurisdictions, (xi)
our reliance on single suppliers for certain product components,
(xii) the fact that we will need to raise additional capital to
meet our business requirements in the future and that such capital
raising may be costly, dilutive or difficult to obtain and (xiii)
the fact that we conduct business in multiple foreign
jurisdictions, exposing us to foreign currency exchange rate
fluctuations, logistical and communications challenges, burdens and
costs of compliance with foreign laws and political and economic
instability in each jurisdiction. More detailed information about
the Company and the risk factors that may affect the realization of
forward looking statements is set forth in the Company's filings
with the Securities and Exchange Commission (SEC), including the
Company's Annual Report on Form 10-K and its Quarterly Reports on
Form 10-Q. Investors and security holders are urged to read these
documents free of charge on the SEC's web site
at http://www.sec.gov. The Company assumes no obligation to
publicly update or revise its forward-looking statements as a
result of new information, future events or otherwise.
Investor Contacts:
InspireMD, Inc.
Craig Shore
Chief Financial Officer
Phone: 1-888-776-6804 FREE
Email: craigs@inspiremd.com
Crescendo Communications, LLC
David Waldman
Phone: (212) 671-1021
Email: NSPR@crescendo-ir.com